Overview

Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI

Status:
Terminated
Trial end date:
2021-09-07
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if ferumoxytol, when given at the time of a magnetic resonance imaging (MRI), can help researchers learn more about the spread of certain kinds of cancers. Ferumoxytol is designed to deliver iron to treat iron-deficiency anemia (low red blood cell counts) in patients with chronic kidney disease. In this study, it will be used as an MRI contrast. Contrasts are used by doctors in order to see MRI images more clearly.
Phase:
Early Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Ferrosoferric Oxide